Dashboard
Manage Tickers

GLPGGALAPAGOS NV

Nasdaq glpg.com


$ 24.22 $ -0.26 (-1.06 %)    

Wednesday, 14-Aug-2024 15:59:47 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.74 $ 0.15 (0.03 %)
DIA $ 400.12 $ 2.30 (0.58 %)
SPY $ 543.85 $ 1.71 (0.32 %)
TLT $ 97.88 $ 0.61 (0.63 %)
GLD $ 226.19 $ -1.86 (-0.82 %)
$ 24.2
$ 24.20 x 100
-- x --
-- - --
$ 24.16 - $ 42.46
53,996
na
1.59B
$ 0.84
$ 6.81
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-approves-adaptimmune-therapeutics-engineered-cell-therapy-as-first-for-solid-tumor-and-new-therapy-for-rare-soft-tissue-cancer-in-over-a-decade
FDA Approves Adaptimmune Therapeutics' Eng...
08/02/2024 12:46:46

FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large jo...

galapagos-q2-2024-adj-eps-151-beats-004-estimate-sales-14030m-beat-6475m-estimate
Galapagos Q2 2024 Adj EPS $1.51 Beats $(0....
08/01/2024 20:06:43

Galapagos (NASDAQ:GLPG) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $(0.04) by ...

bridgene-biosciences-expands-collaboration-with-galapagos-nv-eligible-to-receive-up-to-159m-in-total-payments-partnership-focuses-on-discovery-of-highly-selective-oral-smarca2-protac
BridGene Biosciences Expands Collaboration...
08/01/2024 20:02:49

galapagos-to-present-data-on-cd19-car-t-candidate-glpg5101-for-relapsedrefractory-non-hodgkin-lymphoma-at-eha-2024
Galapagos To Present Data On CD19 CAR-T Ca...
06/14/2024 20:03:11

Core News & Articles
Galapagos And Adaptimmune Enter Clinical C...
05/30/2024 20:02:10

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next gener...

galapagos-and-blood-centers-of-america-collaborate-to-expand-galapagos-decentralized-car-t-manufacturing-network-in-the-us
Galapagos And Blood Centers Of America Col...
05/15/2024 20:03:06

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product ...

galapagos-q1-eps-140-vs-040-yoy-revenue-624-million-vs-586-million-yoy
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Reven...
05/02/2024 20:37:56

Results from our continuing operationsTotal operating loss from continuing operations for the three months ended 31 March 2024 ...

morgan-stanley-maintains-equal-weight-on-galapagos-maintains-38-price-target
Morgan Stanley Maintains Equal-Weight on G...
04/22/2024 17:23:34

Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.

galapagos-plans-clinical-and-translational-data-presentations-at-ebmt-congress-2024
Galapagos Plans Clinical And Translational...
04/04/2024 20:03:43

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL...

galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress-analyst
Galapagos Downgraded, Pharma Firm Faces Up...
04/01/2024 18:37:03

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded m...

b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31
B of A Securities Downgrades Galapagos to ...
04/01/2024 11:07:37

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31
B of A Securities Downgrades Galapagos to ...
03/28/2024 10:20:03

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

morgan-stanley-assumes-galapagos-at-equal-weight-announces-price-target-of-38
Morgan Stanley Assumes Galapagos at Equal-...
03/07/2024 09:20:00

Morgan Stanley analyst Judah Frommer assumes Galapagos (NASDAQ:GLPG) with a Equal-Weight rating and announces Price Target o...

galapagos-expects-fy24-further-reduction-in-cash-burn-and-expect-cash-burn-to-be-280m-320m
Galapagos Expects FY24 Further Reduction I...
02/22/2024 21:12:43

galapgos-fy23-eps-321-up-from-332-yoy-revenue-7835m
Galapgos FY23 EPS €3.21 Up From €(3.32) Yo...
02/22/2024 21:08:06

earnings-scheduled-for-february-22-2024
Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

galapagos-to-present-new-preliminary-translational-data-and-previously-disclosed-data-from-euplagia-1-phase-12-study-at-the-european-society-for-blood-and-marrow-transplantation---8k
Galapagos To Present New Preliminary Trans...
02/16/2024 11:10:01

The preliminary translational data demonstrate that Galapagos’ differentiated point-of-care manufacturing platform offers the p...

Core News & Articles
Galapagos Enters Strategic Collaboration D...
01/04/2024 21:08:02

european-drugmaker-galapagos-collaborates-with-biotech-bridgene-biosciences-to-develop-cancer-treatments
European Drugmaker Galapagos Collaborates ...
01/03/2024 21:01:44

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...

bridgene-says-galapagos-will-pay-up-to-27m-in-upfront-and-preclinical-research-milestone-payments-more-than-700m-in-clinical-and-commercial-milestones-eligible-to-receive-tiered-royalties-on-net-sales-of-each-product-resulting-from-the-collaboration
BridGene Says "Galapagos Will Pay Up To $2...
01/03/2024 21:01:02

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION